Compare AMR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | ELVN |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2017 | 2020 |
| Metric | AMR | ELVN |
|---|---|---|
| Price | $187.20 | $44.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $181.50 | $43.40 |
| AVG Volume (30 Days) | 244.2K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,129,481,000.00 | N/A |
| Revenue This Year | $13.55 | N/A |
| Revenue Next Year | $13.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $102.13 | $14.79 |
| 52 Week High | $253.82 | $46.31 |
| Indicator | AMR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 71.84 |
| Support Level | $151.08 | $18.04 |
| Resistance Level | $187.87 | N/A |
| Average True Range (ATR) | 11.63 | 2.75 |
| MACD | -2.74 | 0.61 |
| Stochastic Oscillator | 11.05 | 87.73 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.